Dong-A to develop molecular diagnostic technology

Published: 2011-07-28 06:56:00

Updated: 2011-07-28 06:56:00

Dong-A Pharmaceutical and the US-based Nanogea announced on July 22 that both companies have signed a letter of intent for the co-development and commercialization of new molecular diagnostics, using the latter’s proprietary NanoCone-Enabled Atomic Microscopy technology to detect Prostate Specifi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK